Shiki, Japan

Masataka Hikota

This inventor holds 9 USPTO granted patents and 1 EPO patent. Top assignees: Tanabe Seiyaku Company, Limited, Mitsubishi Tanabe Pharma Corporation. Active years: 1995-2010.


% Patents Active = 22.2


Average Co-Inventor Count = 4.5

ph-index = 4

Forward Citations = 66(Granted Patents)


Location History:

  • Shiki, JP (1995 - 2010)
  • Osaka, JP (2010)

Company Filing History:


Years Active: 1995-2010

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Masataka Hikota: Innovator in Pharmaceutical Chemistry

Introduction

Masataka Hikota is a prominent inventor based in Shiki, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 9 patents. His work focuses on innovative compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents is a method for preparing a Norvaline derivative, which includes a pharmaceutical composition that can inhibit the transporting activity of glycine transporter type 2 (GlyT2). This invention is crucial for developing treatments for various neurological conditions. Another notable patent involves a nitrogen-containing 5-membered ring compound, which presents new possibilities in medicinal chemistry.

Career Highlights

Masataka Hikota has worked with reputable companies such as Tanabe Seiyaku Company, Limited and Mitsubishi Tanabe Pharma Corporation. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in pharmaceuticals.

Collaborations

Throughout his career, Hikota has collaborated with esteemed colleagues, including Kosuke Yasuda and Hiroshi Morimoto. These partnerships have fostered a creative environment that has led to innovative solutions in drug development.

Conclusion

Masataka Hikota's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the field. His work continues to influence the development of new therapeutic agents.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…